Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir

Jonas Schreiber, John McNally, Krishna Chodavarapu, Evguenia Svarovskaia, Christophe Moreno – 14 May 2016 – During a phase 3 study evaluating the combination of sofosbuvir‐velpatasvir for 12 weeks in patients with genotype 1, 2, 4, 5, and 6 hepatitis C virus (HCV) infection, we enrolled a patient who was subsequently found to be infected with genotype 7 HCV. This patient tolerated the study regimen well and achieved sustained virological response 12 weeks after treatment (SVR12). (Hepatology 2016;64:983‐985)

Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir

Jonas Schreiber, John McNally, Krishna Chodavarapu, Evguenia Svarovskaia, Christophe Moreno – 14 May 2016 – During a phase 3 study evaluating the combination of sofosbuvir‐velpatasvir for 12 weeks in patients with genotype 1, 2, 4, 5, and 6 hepatitis C virus (HCV) infection, we enrolled a patient who was subsequently found to be infected with genotype 7 HCV. This patient tolerated the study regimen well and achieved sustained virological response 12 weeks after treatment (SVR12). (Hepatology 2016;64:983‐985)

Chronic expression of interferon‐gamma leads to murine autoimmune cholangitis with a female predominance

Heekyong R. Bae, Patrick S.C. Leung, Koichi Tsuneyama, Julio C. Valencia, Deborah L. Hodge, Seohyun Kim, Tim Back, Megan Karwan, Anand S. Merchant, Nobuyuki Baba, Dechun Feng, Ogyi Park, Bin Gao, Guo‐Xiang Yang, M. Eric Gershwin, Howard A. Young – 14 May 2016 – In most autoimmune diseases the serologic hallmarks of disease precede clinical pathology by years. Therefore, the use of animal models in defining early disease events becomes critical.

Subscribe to